Bladder cancer working group report

Japanese Journal of Clinical Oncology

Volumn 40, Issue SUPPL. 1, 2010, Pages

  Kakehi, Yoshiyuki ^a   Hirao, Yoshihiko ^b   Kim, Wun Jae ^c   Ozono, Seiichiro ^d   Masumori, Naoya ^e   Miyanaga, Naoto ^f   Nasu, Yasutomo ^g   Yokomizo, Akira ^h  

^a KAGAWA UNIVERSITY   (Japan)

^b NARA MEDICAL UNIVERSITY   (Japan)

^c Chungbuk National University Hospital   (South Korea)

^d HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e SAPPORO MEDICAL UNIVERSITY   (Japan)

^f UNIVERSITY OF TSUKUBA   (Japan)

^g OKAYAMA UNIVERSITY   (Japan)

^h KYUSHU UNIVERSITY   (Japan)

Author keywords

Bladder cancer; Epidemiology; Risk factors

Indexed keywords

GLUTATHIONE TRANSFERASE; TRIHALOMETHANE;

ARTICLE; BLADDER CANCER; CANCER MORTALITY; CANCER RISK; FOOD INTAKE; GENE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HEALTH EDUCATION; HUMAN; INCIDENCE; LIFESTYLE; NAT2 GENE; OGG1 GENE; UROGENITAL TRACT CANCER; UROTHELIAL CARCINOMA; FEMALE; GENETIC PREDISPOSITION; GENETICS; MALE; RISK FACTOR; SMOKING; URINARY BLADDER NEOPLASMS;

FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LIFE STYLE; MALE; RISK FACTORS; SMOKING; URINARY BLADDER NEOPLASMS;

EID: 77957256520     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyq128     Document Type: Article

References (32)

1. Kirkali Z, Chan T, Manoharan M, Algaba F, Sesterhenn IA, Tachibana M, et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 2005;66:4-34.
2. Wu X, Ros MM, Gu J, Kiemeney L. Epidemiology and genetic susceptibility to bladder cancer. BJU Int 2008;102:1207-15.
3. Prout GR, Jr, Wesley MN, McCarron PG, Chen VW, Greenberg RS, Edwards BK, et al., Survival experience of black patients and white patients with bladder carcinoma. Cancer 2004;100:621-30.
4. Cancer Registration Committee of the Japanese Urological Association. The Report of Clinical Statistical Studies on Registered Bladder Cancer Patients in Japan 1999-2001. Nippon Hinyokika Gakkai Zasshi 2006; 97 (Japanese).
5. Golka K, Heitmann P, Gieseler F, Hodzic J, Masche N, Geller F, et al. Elevated bladder cancer risk due to colorants-a state wide case-control study in North Rhine-Westphalia, Germany. J Toxicol Environ Health A 2008;71:851-5.
6. Kobrosly RW, Meliker JR, Nriagu JO. Automobile industry occupations and bladder cancer: a population-based case-control study in southeastern Michigan, USA. Occup Environ Med 2009;66:650-6.
7. Kwong RC, Karagas MR, Kelsey KT, Schned AR, Marsit CJ, Andrew AS, et al., Arsenic exposure predicts bladder cancer survival in a US population. World J Urol 2010;28:487-92.
8. Villanueva CM, Cantor KP, Grimalt JO, Real FX, Dosemeci M, Kogevinas M, et al., Bladder cancer and exposure to water disinfection by-products through ingestion, bathing, showering, and swimming in pools. Am J Epidemiol 2007;165:148-56.
9. De Stefani E, Deneo-Pellegrini H, Boffetta P, Mendilaharsu M, Brennan P, Ferro G, et al., Dietary patterns and risk of cancer: a factor analysis in Uruguay. Int J Cancer 2009;124:1391-7.
10. Hu J, La Vecchia C, DesMeules M, Negri E, Mery L, Canadian Cancer Registries Epidemiology Research Group. Meat and fish consumption and cancer in Canada. Nutr Cancer 2008;60:313-24.
11. Larsson SC, Johansson JE, Andersson SO, Wolk A. Meat intake and bladder cancer risk in a Swedish prospective cohort. Cancer Causes Control 2009;20:35-40.
12. Anastasiou I, Mygdalis V, Mihalakis A, Adamakis I, Constantinides C, Mitropoulos D. Patient awareness of smoking as a risk for bladder cancer. Int Urol Nephrol 2010;42:309-14.
13. Ponder BA. Cancer genetics. Nature 2001;411:336-41.
14. GreenJ,BanksE,BerringtonA,DarbyS,DeoH,NewtonR. N-acetyltransferase 2 and bladder cancer: an overview and consideration of the evidence for gene-environment interaction. Br J Cancer 2000;83:412-7.
15. Marcus PM, Hayes RB, Vineis P, Garcia-Closas M, Caporaso NE, Autrup H, et al., Cigarette smoking, N-acetyltransferase 2 acetylation status, and bladder cancer risk: a case-series metaanalysis of a gene-environment interaction. Cancer Epidemiol Biomarkers Prev 2000;9:461-7.
16. Vineis P, Marinelli D, Autrup H, Brockmoller J, Cascorbi I, Daly AK, et al., Current smoking, occupation, N-acetyltransferase-2 and bladder cancer: a pooled analysis of genotype-based studies. Cancer Epidemiol Biomarkers Prev 2001;10:1249-52.
17. Grant DM, Tang BK, Kalow W. Polymorphic N-acetylation of a caffeine metabolite. Clin Pharmacol Ther 1983;33:355-9.
18. Sinues B, Perez J, Bernal ML, Saenz MA, Lanuza J, Bartolome M. Urinary mutagenicity and N-acetylation phenotype in textile industry workers exposed to arylamines. Cancer Res 1992;52:4885-9.
19. Kim WJ, Lee HL, Lee SC, Kim YT, Kim H. Polymorphisms of N-acetyltransferase 2, glutathione S-transferase mu and theta genes as risk factors of bladder cancer in relation to asthma and tuberculosis. JUrol2000;164:209-13.
20. Katoh T, Inatomi H, Kim H, Yang M, Matsumoto T, Kawamoto T. Effects of glutathione S-transferase (GST) M1 and GSTT1 genotypes on urothelial cancer risk. Cancer Lett 1998;132:147-52.
21. Ryk C, Berggren P, Kumar R, Hemminki K, Larsson P, Steineck G, et al., Influence of GSTM1, GSTT1, GSTP1 and NAT2 genotypes on the p53 mutational spectrum in bladder tumours. Int J Cancer 2005;113:761-8.
22. Brockmoller J, Cascorbi I, Kerb R, Roots I. Combined analysis of inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1, microsomal epoxide hydrolase, and cytochrome P450 enzymes as modulators of bladder cancer risk. Cancer Res 1996;56:3915-25.
23. Kim WJ., Kim H., Kim CH., Lee MS., Oh BR., Lee HM., et al. GSTT1-null genotype is a protective factor against bladder cancer. Urology 2002;60:913-8.
24. Lee YS, Lee HS, Park MK, Hwang ES, Park EM, Kasai H, et al. Identification of 8-hydroxyguanine glycosylase activity in mammalian i64 Epidemiological risk factors of bladder cancer tissues using 8-hydroxyguanine specific monoclonal antibody. Biochem Biophys Res Commun 1993;196:1545-51.
25. Tchou J, Kasai H, Shibutani S, Chung MH, Laval J, Grollman AP, et al. 8-oxoguanine (8-hydroxyguanine) DNA glycosylase and its substrate specificity. Proc Natl Acad Sci USA 1991;88:4690-4.
26. Kim EJ, Jeong P, Quan C, Kim J, Bae SC, Yoon SJ, et al. Genotypes of TNF-alpha, VEGF, hOGG1, GSTM1, and GSTT1: useful determinants for clinical outcome of bladder cancer. Urology 2005;65:70-5.
27. Kim E-J, Jeong P, Jung CG, Kim W-J. Polymorphisms of human 8-oxoguanine glycosylase1 (hOGG1) in bladder tumor. Korean J Urol 2002;43:213-8.
28. Sasaki M, Nakajima K, Perinchery G, Fujino T, Oh BR, Fujimoto S., et al. Frequent genotype changes at 2308 of the human tumor necrosis factor-alpha promoter region in human uterine endometrial cancer. Oncol Rep 2000;7:369-73.
29. Warzocha K, Ribeiro P, Bienvenu J, Roy P, Charlot C, Rigal D, et al. Genetic polymorphisms in the tumor necrosis factor locus influence non-Hodgkin's lymphoma outcome. Blood 1998;91:3574-81.
30. Jeong P, Kim EJ, Kim EG, Byun SS, Kim CS, Kim WJ. Association of bladder tumors and GA genotype of 2308 nucleotide in tumor necrosis factor-alpha promoter with greater tumor necrosis factor-alpha expression. Urology 2004;64:1052-6.
31. Song DK, Xing DL, Zhang LR, Li ZX, Liu J, Qiao BP. Association of NAT2, GSTM1, GSTT1, CYP2A6, and CYP2A13 gene polymorphisms with susceptibility and clinicopathologic characteristics of bladder cancer in Central China. Cancer Detect Prev 2009;32:416-23.
32. Guey LT, García-Closas M, Murta-Nascimento C, Lloreta J, Palencia L, Kogevinas M, et al. for the EPICURO/Spanish Bladder Cancer Study Investigators. Genetic susceptibility to distinct bladder cancer subphenotypes. Eur Urol 2010 57:283-92.